Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)

Completed · Phase 2

Conditions studied: Graft Vs Host Disease

In brief

To establish the safety and efficacy of two dose levels of ex-vivo cultured adult human mesenchymal stem cells (hMSCs) (Prochymal®) in participants experiencing acute GVHD, Grades II-IV, post hematopoietic stem cells (HSC) transplant.

Key facts

Study ID

NCT00136903

Run by

Mesoblast, Inc.

People needed

32

Starts

2005-04-27

Expected to finish

2008-07-14

Last updated by the study team

2022-01-31

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

• St. Francis Hospital — Indianapolis, Indiana, United States
• Kansas City Cancer Centers - BMT — Kansas City, Missouri, United States
• The Cancer Center at Hackensack University — Hackensack, New Jersey, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• Mt. Sinai Hospital — New York, New York, United States
• University of Rochester — Rochester, New York, United States
• New York Medical College — Valhalla, New York, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Medical College of Wisconsin, FEC — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.